Triple therapy with valsartan, tripterygium glucosides and ligustrazine for proteinuria associated with diabetic nephropathy

Objective To observe the efficacy and safety of triple therapy with valsartan,tripterygium glucosides and ligustrazine in the treatment of proteinuria associated with diabetic nephropathy.Methods 66 patients with diabetic nephropathy (according to 300 mg / 24 h ＞ trace albumin discharge rate (UAER) or 30 mg / 24 h,24 h urine protein was 1.0 g) were selected as subject and then divided into a study group and a control group,36 for the control group and 30 for the study group.In addition to conventional treatment,the control group received valsartan and the study group received valsartan,tripterygium glucosides,and ligustrazine.24-h urine protein,urinary albumin discharge rate (UAER),serum creatinine (SCr) and urea nitrogen (BUN),liver zymology change,glycosylated hemoglobin (HbA 1 c) and blood count were observed in both groups before and after treatment and then were compared between the two groups.Results After treatment,24-h urine protein and UAER were declined significantly in the study group,as compared with the control group (P＜0.05),while levels of HbA1c,serum creatinine,blood urea nitrogen,cereal third transaminase enzyme and routine blood count had no statistical significance (P＞0.05) between the two groups before and after treatment.Conclusions In addition to conventional treatment,triple therapy with valsartan,tripterygium glucosides,and ligustrazine is effective and safe in the treatment of proteinuria associated with diabetic nephropathy,effectively reducing the level of proteinuria in patients.It is safe and worth popularizing clinically. Key words: Valsartan; Tripterygium glucosides; Ligustrazine; Diabetic nephropathy